期刊文献+

Dipeptidyl peptidase-4: A key player in chronic liver disease 被引量:25

Dipeptidyl peptidase-4: A key player in chronic liver disease
在线阅读 下载PDF
导出
摘要 Dipeptidyl peptidase-4 (DPP-4) is a membrane-associated peptidase, also known as CD26. DPP-4 has widespread organ distribution throughout the body and exerts pleiotropic effects via its peptidase activity. A representative target peptide is glucagon-like peptide-1, and inactivation of glucagon-like peptide-1 results in the development of glucose intolerance/diabetes mellitus and hepatic steatosis. In addition to its peptidase activity, DPP-4 is known to be associated with immune stimulation, binding to and degradation of extracellular matrix, resistance to anti-cancer agents, and lipid accumulation. The liver expresses DPP-4 to a high degree, and recent accumulating data suggest that DPP-4 is involved in the development of various chronic liver diseases such as hepatitis C virus infection, non-alcoholic fatty liver disease, and hepatocellular carcinoma. Furthermore, DPP-4 occurs in hepatic stem cells and plays a crucial role in hepatic regeneration. In this review, we described the tissue distribution and various biological effects of DPP-4. Then, we discussed the impact of DPP-4 in chronic liver disease and the possible therapeutic effects of a DPP-4 inhibitor. Dipeptidyl peptidase-4 (DPP-4) is a membrane-associated peptidase, also known as CD26. DPP-4 has widespread organ distribution throughout the body and exerts pleiotropic effects via its peptidase activity. A representative target peptide is glucagon-like peptide-1, and inactivation of glucagon-like peptide-1 results in the development of glucose intolerance/diabetes mellitus and hepatic steatosis. In addition to its peptidase activity, DPP-4 is known to be associated with immune stimulation, binding to and degradation of extracellular matrix, resistance to anti-cancer agents, and lipid accumulation. The liver expresses DPP-4 to a high degree, and recent accumulating data suggest that DPP-4 is involved in the development of various chronic liver diseases such as hepatitis C virus infection, non-alcoholic fatty liver disease, and hepatocellular carcinoma. Furthermore, DPP-4 occurs in hepatic stem cells and plays a crucial role in hepatic regeneration. In this review, we described the tissue distribution and various biological effects of DPP-4. Then, we discussed the impact of DPP-4 in chronic liver disease and the possible therapeutic effects of a DPP-4 inhibitor.
出处 《World Journal of Gastroenterology》 SCIE CAS 2013年第15期2298-2306,共9页 世界胃肠病学杂志(英文版)
关键词 INCRETIN Viral hepatitis Insulin resistance STEATOHEPATITIS Cancer SITAGLIPTIN VILDAGLIPTIN ALOGLIPTIN Teneligliptin LINAGLIPTIN Incretin Viral hepatitis Insulin resistance Steatohepatitis Cancer Sitagliptin Vildagliptin Alogliptin Teneligliptin Linagliptin
  • 相关文献

参考文献8

  • 1Takumi Kawaguchi,Michio Sata.Importance of hepatitis C virus-associated insulin resistance:Therapeutic strategies for insulin sensitization[J].World Journal of Gastroenterology,2010,16(16):1943-1952. 被引量:14
  • 2Atsunori Tsuchiya,Michitaka Imai,Hiroteru Kamimura,Masaaki Takamura,Satoshi Yamagiwa,Tatsuki Sugiyama,Minoru Nomoto,Toshio Heike,Takashi Nagasawa,Tatsutoshi Nakahata,Yutaka Aoyagi.Increased Susceptibility to Severe Chronic Liver Damage in CXCR4 Conditional Knock-Out Mice[J].Digestive Diseases and Sciences.2012(11)
  • 3Yuichiro Eguchi,Hideyuki Hyogo,Masafumi Ono,Toshihiko Mizuta,Naofumi Ono,Kazuma Fujimoto,Kazuaki Chayama,Toshiji Saibara.Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study[J].Journal of Gastroenterology.2012(5)
  • 4Samantha W. M. Lun,C. K. Wong,Fanny W. S. Ko,David S. C. Hui,Christopher W. K. Lam.Increased Expression of Plasma and CD4+ T Lymphocyte Costimulatory Molecule CD26 in Adult Patients with Allergic Asthma[J].Journal of Clinical Immunology.2007(4)
  • 5Garth H Ballantyne MD, FACS, FASCRS.Peptide YY(1-36) and Peptide YY(3-36): Part II. Changes after Gastrointestinal Surgery and Bariatric Surgery: Part I. Distribution, Release and Actions appeared in the last issue (May 2006)[J].Obesity Surgery.2006(6)
  • 6Garth H Ballantyne MD, FACS, FASCRS.Peptide YY(1-36) and Peptide YY(3-36): Part I. Distribution, Release and Actions[J].Obesity Surgery.2006(5)
  • 7J. J. Holst.Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005[J].Diabetologia.2006(2)
  • 8V?in? K. Hopsu-Havu,George G. Glenner.A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-β-naphthylamide[J].Histochemie.1966(3)

共引文献13

同被引文献94

引证文献25

二级引证文献130

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部